Recruiting NCT07045688
Efficacy of Vonoprazan Based Dual and Triple Therapy for Patient With Helicobacter Pylori Infection
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Efficacy of Vonoprazan based dual therapy for naive patient with Helicobacter Pylori infection, Efficacy of Vonoprazan based triple therapy for naive patient with Helicobacter Pylori infection, Efficacy of PPI based triple therapy for naive patient with Helicobacter Pylori infection.
- Who it may be relevant to
- Registry conditions: H. Pylori Infection. Basic parameters: from 19 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Efficacy of Vonoprazan Based Dual and Triple Therapy for Naive Patient With Helicobacter Pylori Infection
Overview
This study aims to assess Efficacy of vonoprazan based dual and triple therapy for naïve patient with Helicopacter Pylori infection in Sohag Government .
Interventions
- Drug Efficacy of Vonoprazan based dual therapy for naive patient with Helicobacter Pylori infection
we assess the efficacy of Vonoprazan based dual therapy for eradication of Helicobacter Pylori infection in naive patient. - Drug Efficacy of Vonoprazan based triple therapy for naive patient with Helicobacter Pylori infection
we assess the efficacy of Vonoprazan based triple therapy for eradication of Helicobacter Pylori infection in naive patient. - Drug Efficacy of PPI based triple therapy for naive patient with Helicobacter Pylori infection
we assess the efficacy of PPI based triple therapy for eradication of Helicobacter Pylori infection in naive patient.
Primary outcome measures
- efficacy medical treatment for eradication of Helicobacter Pylori infection in naive patient. [Time frame: 4 weeks after successful medical treatment]
Eligibility criteria
Inclusion criteria
- Age: >18 years old.
- H. pylori infection: Confirmed by histopathology or non-invasive tests (e.g., stool antigen test).
Exclusion criteria
- Prior H. pylori treatment: Previous treatment for H. pylori infection.
- Allergies: Known allergies to study medications or components.
- Patients cannot finish treatment course.
- Patient missed follow up.
- Patients refusing or neglecting test of cure for H. pylori.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Egypt · 1 center
- Sohag University Hospital — Sohag
Publications
- Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017 Jan;66(1):6-30. doi: 10.11 PMID 27707777
- Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017 Feb;112(2):212-239. doi: 10.1038/ajg.2016.563. Epub 2017 Jan 10. PMID 28071659
- Argueta EA, Alsamman MA, Moss SF, D'Agata EMC. Impact of Antimicrobial Resistance Rates on Eradication of Helicobacter pylori in a US Population. Gastroenterology. 2021 May;160(6):2181-2183.e1. doi: 10.1053/j.gastro.2021.02.014. Epub 2021 Feb 9. No abstract available. PMID 33577874
Identifiers
NCT: NCT07045688 · Soh-Med--25-5-10MS